Get started
Author

Jamie M. Freedman

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
2020 · Carlos Salama, Jian Han, et al. · New England Journal of Medicine · 1,302
PDF
Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder
2025 · Reid Robison, Robert Barrow, et al. · JAMA · 49
Identification and Optimization of Anthranilic Sulfonamides as Novel, Selective Cholecystokinin-2 Receptor Antagonists
2006 · Brett D. Allison, Victor K. Phuong, et al. · Journal of Medicinal Chemistry · 38
A Review of the Evolving Landscape of Inclusive Research and Improved Clinical Trial Access
2022 · Shalini V. Mohan, Jamie Freedman · Clinical Pharmacology & Therapeutics · 35
PDF
Advancing Inclusive Research: Establishing Collaborative Strategies to Improve Diversity in Clinical Trials
2022 · Owen Garrick, Ruben Mesa, et al. · Ethnicity & Disease · 24
Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study.
2020 · Matthew Raymond Smith, Karim Fizazi, et al. · Journal of Clinical Oncology · 20
Characterization of 2-(2,6-dichloro-benzyl)-thiazolo[5,4-d]pyrimidin-7-yl]-(4-trifluoromethyl-phenyl)-amine (JNJ-39729209) as a novel TRPV1 antagonist
2011 · Michael P. Maher, Anindya Bhattacharya, et al. · European Journal of Pharmacology · 18
Discovery and synthesis of 6,7,8,9-tetrahydro-5H-pyrimido-[4,5-d]azepines as novel TRPV1 antagonists
2010 · Natalie A. Hawryluk, Jeffrey E. Merit, et al. · Bioorganic & Medicinal Chemistry Letters · 13
Role of CCK and potential utility of CCK1 receptor antagonism in the treatment of pancreatitis induced by biliary tract obstruction
2008 · T D Barrett, W Yan, et al. · British Journal of Pharmacology · 13
PDF
Action for Increasing Diversity, Market Access, and Capacity in Oncology Registration Trials—Is Africa the Answer? Report From a Satellite Session of the Accelerating Anti-Cancer Agent Development and Validation Workshop
2022 · Darya Kizub, Cathyryne K. Manner, et al. · JCO Global Oncology · 12
PDF
Using Patient-Initiated Study Participation in the Development of Evidence for Personalized Cancer Therapy
2011 · Laurie Fenton Ambrose, Jamie Freedman, et al. · Clinical Cancer Research · 7
1,2-Diamino-ethane-substituted-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepines as TRPV1 antagonists with improved properties
2010 · Alec D. Lebsack, Jason C. Rech, et al. · Bioorganic & Medicinal Chemistry Letters · 7
JNJ-26070109 [(R)4-Bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: A Novel, Potent, and Selective Cholecystokinin 2 Receptor Antagonist with Good Oral Bioavailability
2011 · Magda F. Morton, Terrance D. Barrett, et al. · Journal of Pharmacology and Experimental Therapeutics · 6
3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1 H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a Novel, Potent, and Selective Cholecystokinin 1 Receptor Antagonist: In Vitro and in Vivo Pharmacological Comparison with Dexloxiglumide
2007 · Magda F. Morton, Terrance D. Barrett, et al. · Journal of Pharmacology and Experimental Therapeutics · 6
A novel, quantitative bio-assay for cholecystokinin type-1 receptor activity in the anaesthetised rat
2005 · Jamie M. Freedman, Terrance D. Barrett, et al. · Journal of Pharmacological and Toxicological Methods · 2
PCR11 Clinical Trial Participant and Clinician Experience in a Phase 2 (US-only) Trial of MM120 for Generalized Anxiety Disorder
2025 · Dawn Bates, Phong Duong, et al. · Value in Health
Pharmacological Characterization of a Purinergic Receptor (p2x7) Antagonist In‐vitro and In‐vivo
2010 · Anindya Bhattacharya, Michael P Maher, et al. · The FASEB Journal
Works count: 17
Citation count: 1,552
H-index: 10
I10-index: 10
Year
Topic
Type